Physician profile
Merritt E Keys
NPI 1972029031
$7,837.06
in general payments reported to CMS, 2019-2025
22 companies · $943 in 2025
The $943 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,497 · 2022: $2,096 · 2023: $1,240 · 2024: $1,061 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,244.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,986.71 | 2021-2025 | |
| Amgen INC. | $472.28 | 2021-2023 | Aimovig |
| Biohaven Pharmaceuticals, INC. | $311.37 | 2021 | |
| Lilly USA, LLC | $287.66 | 2021-2024 | Emgality, Reyvow |
| Pfizer INC. | $231.25 | 2023-2025 | |
| Eisai INC. | $206.72 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $184.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $179.54 | 2021-2022 | |
| Allergan, INC. | $174.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $166.25 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $118.49 | 2021 | |
| Genzyme Corporation | $118.35 | 2021 | |
| Sk Life Science, INC. | $91.27 | 2025 | |
| Neurocrine Biosciences, INC. | $65.53 | 2024-2025 | Ingrezza |
| Ucb, INC. | $47.84 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $45.71 | 2021 | |
| Upsher-Smith Laboratories LLC | $43.92 | 2021 | |
| Acadia Pharmaceuticals INC | $35.78 | 2021-2024 | Nuplazid |
| Lundbeck LLC | $26.00 | 2021-2024 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.65 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $13.44 | 2022 | |
| Almatica Pharma LLC | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merritt Keys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.